--- title: Community Engagement Throughout Drug Development & Commercialization description: In drug development, community engagement is often relegated to post-launch marketing efforts. But what if we integrate it along the entire continuum?  image: https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Launch-Lens--Weaving-Community-Engagement-Throughout-Drug-Development-%26-Commercialization.jpg --- [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate-logo.png?width=2000&height=497&name=Acclinate-logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [eDICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [Contract Research Organizations](https://www.acclinate.com/solutions/for-cros) - [Partners](https://www.acclinate.com/solutions/community-partners) - Company - [About Us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [News](https://news.acclinate.com) - Resources - [Resource Library](https://www.acclinate.com/resources) - [Blog](https://blog.acclinate.com) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [Glossary](https://www.acclinate.com/glossary) - [FAQ](https://www.acclinate.com/faq) - [Talk to Our Team](https://info.acclinate.com/get-in-touch) [![Talk to Our Team](https://no-cache.hubspot.com/cta/default/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302.png)](https://cta-redirect.hubspot.com/cta/redirect/19943632/2e1c34dc-aaa1-43b8-b5f4-469b0db4e302) [![Acclinate Logo](https://blog.acclinate.com/hs-fs/hubfs/Acclinate_Logo.png?width=500&height=149&name=Acclinate_Logo.png "Acclinate Logo")](https://www.acclinate.com/) - Products - [**NOWINCLUDED**Acclinate’s B2C community platform ](https://www.acclinate.com/products/nowincluded-the-community) - [**e-DICT**Acclinate’s patented AI-powered technology ](https://www.acclinate.com/products/e-dict) - Solutions - [**Pharmaceutical Companies**Community-driven recruitment and real-world insights to support diverse, compliant clinical trials. ](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [**Contract Research Organization (CRO)**Scalable patient engagement and recruitment solutions that reduce risk and improve enrollment timelines. ](https://www.acclinate.com/solutions/for-cros) - [**Partners**Trusted partnerships that connect research opportunities with the communities they aim to serve. ](https://www.acclinate.com/solutions/community-partners) - Company - [**About us**We help clinical research teams reach diverse communities, build trust, and improve trial participation. ](https://www.acclinate.com/about) - [**Careers**Join a mission-driven team advancing inclusive clinical research and community-powered health innovation. ](https://www.acclinate.com/careers) - Resources - [**Resources Hub** ](https://www.acclinate.com/resources) - [**Glossary** ](https://www.acclinate.com/glossary) - [**Press Kit** ](https://www.acclinate.com/press-kit) - [**Events** ](https://www.acclinate.com/events) - [**Blog** ](https://blog.acclinate.com/) - [**News** ](https://news.acclinate.com/) - [![](https://cdn.prod.website-files.com/695fbca039298e2117988a78/69e7b588548c7ad7bd8ab0bc_9dd915489696393dc63d7785ee2e52c7_Question%20mark%20image.png) **FAQs** ](https://www.acclinate.com/faq) - [ Contact Us ](https://www.acclinate.com/contact-us) Stay up to date Get news directly in your inbox Topic All - [Affective Trust ](https://blog.acclinate.com/tag/affective-trust) - [Announcement ](https://blog.acclinate.com/tag/announcement) - [Clinical Research Software ](https://blog.acclinate.com/tag/clinical-research-software) - [Clinical Trial Recruitment Strategies ](https://blog.acclinate.com/tag/clinical-trial-recruitment-strategies) - [Community ](https://blog.acclinate.com/tag/community) - [Diversity in Clinical Trials ](https://blog.acclinate.com/tag/diversity-in-clinical-trials) - [e-DICT™ ](https://blog.acclinate.com/tag/e-dict) - [FDA Diversity Plan ](https://blog.acclinate.com/tag/fda-diversity-plan) - [FDA Guidance: Diversity in Clinical Trials ](https://blog.acclinate.com/tag/fda-guidance-diversity-in-clinical-trials) - [Health Equity ](https://blog.acclinate.com/tag/health-equity) - [Partnerships ](https://blog.acclinate.com/tag/partnerships) - [Representation in Healthcare ](https://blog.acclinate.com/tag/representation-in-healthcare) [Diversity in Clinical Trials](https://blog.acclinate.com/topic/diversity-in-clinical-trials) # The Launch Lens: Weaving Community Engagement Throughout Drug Development & Commercialization In drug development, community engagement is often relegated to post-launch marketing efforts. But what if we integrate it along the entire continuum?  ![ The Launch Lens: Weaving Community Engagement Throughout Drug Development & Commercialization](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Launch-Lens--Weaving-Community-Engagement-Throughout-Drug-Development-%26-Commercialization.jpg) Clinical Trial Diversity: What Does It Really Mean? Clinical trials are critical for evaluating the safety and effectiveness of medical devices and pharmaceutical products. The results of trials guide t... Read More ![ Camille Campbell, PharmD, RPh](https://blog.acclinate.com/hubfs/Acclinate/653bee7991e3154115ca2349_person-3.png) [Camille Campbell, PharmD, RPh](https://blog.acclinate.com/author/camille-campbell) Senior Director of Health Equity, Acclinate Share this Post: [**](https://www.facebook.com/sharer/sharer.php?u=https://blog.acclinate.com/the-launch-lens-weaving-community-engagement-throughout-drug-development-commercialization) [**](https://twitter.com/home?status=https://blog.acclinate.com/the-launch-lens-weaving-community-engagement-throughout-drug-development-commercialization) [** ](https://www.linkedin.com/shareArticle?mini=true&url=https://blog.acclinate.com/the-launch-lens-weaving-community-engagement-throughout-drug-development-commercialization&title=Community%20Engagement%20Throughout%20Drug%20Development%20&%20Commercialization) Stay up to date Get news directly in your inbox We pour our efforts into research, striving for breakthroughs that change lives. But are we truly listening to the people who those breakthroughs are meant to help?   I've experienced firsthand how a drug's success doesn’t depend on just scientific innovation, but also on human connection and translating that innovation into improved outcomes for patients and communities. Traditionally, drug development and commercialization have been viewed as linear processes, with community engagement often relegated to post-launch marketing efforts. But what if we took a more holistic approach that integrates community engagement along the entire continuum?    This strategy can have significant benefits, including improved trust (among patients *and* healthcare providers), better trial designs, and potentially increased patient access and adherence.  Let’s use the “drug launch” as an example for exploring how community engagement can be strategically incorporated to enhance development and commercialization processes while supporting underrepresented patient populations.  ## **Pre-Launch Engagement: Laying the Foundation for Success**  I’ve had the opportunity to bring several new indications to market and know that the period leading up to a drug launch (about 1-2 years before the anticipated [PDUFA](https://www.fda.gov/industry/fda-user-fee-programs/prescription-drug-user-fee-amendments#:~:text=Since%20the%20passage%20of%20PDUFA,and%202022%20(PDUFA%20VII).) date) is critical for laying the groundwork for successful commercialization.  As cross-functional teams (i.e., Clinical Development, Clinical Operations, Marketing, Medical Affairs, Patient Advocacy, etc.) prepare for regulatory approval, they can all weave community engagement and the gathering of patient insights into their strategic plans to enhance and inform pre-launch activities.  ### **Improved Clinical Trial Designs and Recruitment**   Community engagement before and during a Phase 3 study (with study enrollment often occurring simultaneously with launch prep) allows for realistic patient perspectives to be incorporated into research protocols—making participation feel less like a clinical trial and more like a shared journey. This can lead to:  - A refinement of study endpoints and reduction of logistical burdens that make recruitment and retention challenging. - Creation of patient-facing materials that truly resonate and inform the community about the chance to participate in the study. - The opportunity to build sustained relationships with community stakeholders and clinical trial sites that encourage recruitment of representative patient populations, helping to ensure results reflect the real world.  ### **Early Disease Education and Awareness**  Engaging patient advocacy groups, community leaders, and community-based providers during pre-launch helps with distribution of accurate and relevant disease information that can be tailored for population-specific needs.  This proactive approach helps address misinformation and build trust within communities early on. I’ve seen how it can be especially impactful when trying to reach underrepresented communities who are often disproportionately impacted by certain conditions, yet overlooked.  ### **Understanding the Clinical Landscape**  Direct engagement with patients, caregivers, and providers during the pre-launch period allows for deeper understanding of aspects related to the clinical landscape, including unmet needs, existing treatment challenges, and patient preferences—which may vary across different subsets of each community.  These insights can inform development of unique commercial strategies that ensure the drug's value proposition resonates with intended audiences. They can also help better define the target product profile, and how it may be differentiated from competitors.  [Discover how Acclinate partnered with a leading biotech company to expand representation in COPD research](https://www.acclinate.com/expanding-representation-in-copd-research).  ## **Drug Launch: The Inflection Point**  The launch period, marked by regulatory approval and branded promotional activities, represents an inflection point—the start of bringing a treatment to market. It isn't just about press releases. It’s also about turning up the volume on community connections that have been previously built. And this step is when community engagement can be amplified to maximize impact.  ### **Amplified Disease Awareness and Education**   By leveraging established relationships with patient advocacy groups and community stakeholders, research sponsors can disseminate educational materials and resources on a wider scale. Using digital platforms and social media can further expand reach for distribution efforts.  In-person community launch events in collaboration with patient advocates, community partners, and key opinion leaders—who are front and center sharing their stories and experiences—can increase visibility of the sponsor, disease state, and branded drug.  ### **Targeted Communication and Support**   Patients aren’t all the same. That’s why personalized communication and support programs matter. Culturally competent materials, financial assistance, and tools that make adherence easier ensure that relevant information is readily available and addresses access needs that may improve treatment outcomes. And leveraging community input in the development of these assets ensures that they are meaningful for intended users.     *“Patients aren’t all the same. That’s why personalized communication and support programs matter.”* ### **Gathering Real-World Evidence**  Collecting patient, caregiver, and prescriber insights during the launch period provides valuable information into the drug's real-world efficacy and safety, along with a better understanding of access challenges.  During my time in the field engaging community members whose insights vary from town to town and zip code to zip code, I learned it’s important to be intentional when collecting data and nuanced when assessing responses.  Results from carefully conducted community listening activities can be used to address patient and prescriber concerns, revise medical affairs and marketing strategies, and inform future research.  ## **Post-Launch Engagement: Continuous Improvement and Long-Term Impact**  The relationship with the community doesn't end after the immediate launch period—conversations must continue throughout the duration of the drug’s lifecycle. Post-launch engagement is essential for sustaining the drug's success and ensuring continual benefit to patients, caregivers, and healthcare providers.  ### **Ongoing Insights Gathering**  It’s important to stay connected. Feedback mechanisms such as community surveys, forums, and patient advisory boards are a means for collecting data points and personal stories that can inform commercial strategies, product improvements, and development of new indications.  ### **Phase 4 Clinical Trials and Real-World Data Collection**  Phase 4 trials, conducted after regulatory approval, may answer additional research questions, and gather real-world evidence on the drug's long-term safety and effectiveness. As with the pre-launch period, community engagement can facilitate recruitment for these trials and ensure that they [include a representative population](https://blog.acclinate.com/inclusive-research-the-key-to-a-healthier-america).  ### **Building and Maintaining Long-Term Partnerships**  Continuing to strengthen relationships with community-based organizations and patient advocacy groups, even after the drug has been on the market for a while, fosters [affective trust](https://blog.acclinate.com/overcome-clinical-trial-recruitment-challenges-start-with-affective-trust) and collaboration, leading to improved outcomes and long-term partnerships that help identify additional unmet needs and drive innovation in future drug development efforts.  ## **Community Is the Key to Impact**  Ultimately, creating new treatments should go beyond developing and commercializing drugs. Integrating community engagement throughout the continuum, with a focus on the launch period as an inflection point, benefits research sponsors (across ALL functional areas) and patients alike. Embracing a community-centric approach that prioritizes collaboration and communication is essential for translating scientific innovation into improved outcomes. It’s key as we strive to achieve health equity for the communities we serve.  Ready to learn more about how Acclinate drives health equity across care? [Connect with our team](https://get.nowincluded.com/cs/c/?cta_guid=06387b94-c49a-4a46-9ace-10df11a46c52&signature=AAH58kEy7tW5J4D29iaKsO9UN_9ny7RKuw&portal_id=19943632&placement_guid=31583cc4-4449-4d4b-8cb9-94b6615b6eee&click=477137ef-2db5-4287-aff3-0f3c3e472724&redirect_url=APefjpFuKofX5kx6fVE7b5q3AJbQBrHkvgUvvOkoAl2RGN4k1qnfz-Bn0m0Ic9fcriPE_PDqlv9Vwom70TFu8mGisJqxVyMwLSq1hRPGnnZRKI59yW5oW1-HW3iD2AgvLMcXEz18RAjkUahbFZIIhN033XkZedOFgTUlXMnlXpi6hs4DEgXgGc_9kmchrtq_KMSCsAm01y2mcHNr3xCZttVDmMrG2uZ9pTI3UmwsYenEI-A7NGl6DVE&hsutk=a29af89f29e0797a58cc6f736ebede31&canon=https%3A%2F%2Fwww.acclinate.com%2F&ts=1742693379391&__hstc=268225873.a29af89f29e0797a58cc6f736ebede31.1737332243479.1742081098986.1742693380891.35&__hssc=268225873.1.1742693380891&__hsfp=2562601565).  [![Increasing Diversity in Clinical Trials](https://no-cache.hubspot.com/cta/default/19943632/interactive-170609956904.png) ](https://blog.acclinate.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKIWXrRihPNiPFfvPM0pD1fOXzi87peGN22X8uZBazFrXu0sZt%2F994yrj5aQ6vizPrZYgQnptc%2FX64uv%2B8TkjasV58vK04EMRDhn1nCwH%2F2yLtz03mN9o85TJPz6O157tbguGFqQUCjFuRiVVFsH8P55e112DWRmB2G98%2Fow7KPfvNM8cmNYWyKyE94I1Tr1Kqmr6h3mOfXAvX4IU7jilvahuNtMKheWyHdZQ%3D%3D&webInteractiveContentId=170609956904&portalId=19943632) ## Recent Posts [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [ Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) June 25, 2026 3 Min Read Drug development economics are changing. Sponsors are increasingly relying on a single pivotal trial to support approval. Though the goal of this appr... Read More [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [ Clinical Trial Generalizability: What Regulators Will Scrutinize Next ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) June 25, 2026 3 Min Read For years, generalizability was framed as a methodological concern. Reviewers debated whether results could reasonably extend beyond a trial’s enrolle... Read More [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) [ Site Engagement Index (SEI): Measuring What Actually Builds Trust ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) June 25, 2026 3 Min Read Clinical research lacks anything but metrics. Enrollment targets, site activation timelines, and digital engagement rates are tracked closely across s... Read More [![](https://blog.acclinate.com/hubfs/Imported_Blog_Media/6567a9f90c0cf111067913e2_Merck%20Pop%20Up2.png) ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) [ Acclinate to support Merck's oncology clinical trials ](https://blog.acclinate.com/acclinate-collaborates-with-merck-to-increase-clinical-trial-diversity) June 24, 2026 1 Min Read Acclinate, an expert in health equity through inclusive research, is collaborating with Merck, known as MSD outside the United States and Canada, to h... Read More [![Why Trial Diversity Is Now a Risk Management Strategy](https://blog.acclinate.com/hubfs/Why-Trial-Diversity-Is-Now-a-Risk-Management-Strategy.jpg) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) [ The New Control Lever: Why Trial Diversity Is Now a Risk Management Strategy ](https://blog.acclinate.com/why-trial-diversity-is-now-a-risk-management-strategy) March 2, 2026 3 Min Read For years, conversations around trial diversity were framed as ethical or reputational concerns. That framing no longer reflects regulatory reality. Read More [![Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity](https://blog.acclinate.com/hubfs/AdobeStock_470269560.webp) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) [ Acclinate’s NOWINCLUDED: Turning Community Insights Into Research Equity ](https://blog.acclinate.com/acclinates-nowincluded-turning-community-insights-into-research-equity) February 16, 2026 3 Min Read Clinical research equity efforts originate with good intentions. But they often hit a roadblock in practice: communities are asked to participate in h... Read More [![How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust](https://blog.acclinate.com/hubfs/AdobeStock_1631551849.webp) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [- [Community](https://blog.acclinate.com/news/tag/community) ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) [ How Acclinate’s e-DICT™ Technology Builds Real-Time Community Trust ](https://blog.acclinate.com/how-acclinates-e-dict-technology-builds-real-time-community-trust) February 9, 2026 3 Min Read Reaching underrepresented communities in healthcare research has never been simple. Participation decisions are shaped by lived experience, historical... Read More [![Data-Driven Inclusion](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Acclinate-Data-Driven-Inclusion.jpg) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [- [Clinical Research Software](https://blog.acclinate.com/news/tag/clinical-research-software) ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) [ Data-Driven Inclusion: Predictive Analytics for Trial Enrollment ](https://blog.acclinate.com/data-driven-inclusion-predictive-analytics-for-trial-enrollment) February 2, 2026 2 Min Read Subpar enrollment remains one of the most common causes of trial delays. But sponsors often miss a key factor: underrepresentation. Lack of diversity ... Read More [![Exploring Diversity in Clinical Research With Acclinate](https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/Exploring-Diversity-in-Clinical-Research-With-Acclinate.jpg) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [- [Diversity in Clinical Trials](https://blog.acclinate.com/news/tag/diversity-in-clinical-trials) ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) [ Exploring Diversity in Clinical Research With Acclinate ](https://blog.acclinate.com/exploring-diversity-in-clinical-research-with-acclinate) January 26, 2026 3 Min Read Diversity in clinical research remains a widely discussed goal, yet progress has been uneven. Trials still grapple with subpar representation, limited... Read More [![Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World](https://blog.acclinate.com/hubfs/mature-female-patient-at-doctors-appointment-2026-01-08-06-10-47-utc.webp) June 25, 2026 Clinical Trial Management: The Hidden Risk of Homogeneous Trials in a One-Pivotal-Study World Read More ](https://blog.acclinate.com/clinical-trial-management-the-hidden-risk-of-homogeneous-trials-in-a-one-pivotal-study-world) [![Clinical Trial Generalizability: What Regulators Will Scrutinize Next](https://blog.acclinate.com/hubfs/woman-visiting-dermatologist-2026-01-08-22-23-31-utc.webp) June 25, 2026 Clinical Trial Generalizability: What Regulators Will Scrutinize Next Read More ](https://blog.acclinate.com/clinical-trial-generalizability-what-regulators-will-scrutinize-next) [![Site Engagement Index (SEI): Measuring What Actually Builds Trust](https://blog.acclinate.com/hubfs/computer-screen-trading-and-back-with-charts-hom-2026-01-09-09-28-19-utc.webp) June 25, 2026 Site Engagement Index (SEI): Measuring What Actually Builds Trust Read More ](https://blog.acclinate.com/site-engagement-index-sei-measuring-what-actually-builds-trust) ![Woman wearing Acclinate Shirt](https://blog.acclinate.com/hs-fs/hubfs/layer1_image.webp?width=1600&height=1068&name=layer1_image.webp) ![Medical Research Software e-DICT](https://blog.acclinate.com/hs-fs/hubfs/layer2_image.webp?width=885&height=885&name=layer2_image.webp) ![layer2.2_image](https://blog.acclinate.com/hs-fs/hubfs/layer2.2_image.webp?width=1505&height=1197&name=layer2.2_image.webp) ![layer3_image](https://blog.acclinate.com/hs-fs/hubfs/layer3_image.webp?width=1600&height=1067&name=layer3_image.webp) ## Ready to Measure Your True Impact? Partner with Acclinate to turn mission into measurable, data-driven action. [ Get Started ](https://www.acclinate.com/contact-us) [![Acclinate Logo Reversed](https://blog.acclinate.com/hs-fs/hubfs/footer_logo.png?width=1600&height=398&name=footer_logo.png "Acclinate Logo Reversed")](https://www.acclinate.com/) - Products - [NOWINCLUDED](https://www.acclinate.com/products/nowincluded-the-community) - [e-DICT](https://www.acclinate.com/products/e-dict) - Solutions - [Pharmaceutical Companies](https://www.acclinate.com/solutions/for-pharmaceutical-companies) - [CROs](https://www.acclinate.com/solutions/for-cros) - [Community Partners](https://www.acclinate.com/solutions/community-partners) - Resources - [Resources Hub](https://www.acclinate.com/resources) - [Glossary](https://www.acclinate.com/glossary) - [Press Kit](https://www.acclinate.com/press-kit) - [Events](https://www.acclinate.com/events) - [News](https://news.acclinate.com/) - [Blog](https://blog.acclinate.com/) - [FAQs](https://www.acclinate.com/faq) - Company - [About us](https://www.acclinate.com/about) - [Careers](https://www.acclinate.com/careers) - [Contact Us](https://www.acclinate.com/contact-us) - Follow Us - [** Linkedin](https://www.linkedin.com/company/acclinateinc/) - [Privacy Policy](https://www.acclinate.com/privacy) - [Terms of Service](https://www.acclinate.com/terms-of-use-acclinate) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Person", "name" : "Camille Campbell, PharmD, RPh", "url" : "https://blog.acclinate.com/author/camille-campbell" }, "dateModified" : "2026-06-18T19:51:04.964Z", "datePublished" : "2025-03-27T17:33:50.000Z", "headline" : "Community Engagement Throughout Drug Development & Commercialization", "image" : [ "https://blog.acclinate.com/hubfs/Acclinate/Blog%20Images/The-Launch-Lens--Weaving-Community-Engagement-Throughout-Drug-Development-&-Commercialization.jpg" ], "mainEntityOfPage" : { "@id" : "https://blog.acclinate.com/the-launch-lens-weaving-community-engagement-throughout-drug-development-commercialization", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://blog.acclinate.com/hubfs/Acclinate-logo.png" }, "name" : "Acclinate" } } ```